J B Chemicals & (JBCHEPHARM)

FairStock Score: 42/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Zero debt with high returns: ROE 21.95% and ROCE 25.79%.
• Strong cash generation: Free cash flow of ₹606 Cr and Piotroski F-Score of 8/9.
• Promoter holding of 48.78% aligns management with minority shareholders.
• Steady compounding: 5-year revenue CAGR of 13.91% and profit growth of 17.77%.
• Financially safe: Altman Z-Score of 7.29 indicates strong solvency.

Concerns

• Very expensive valuation: P/E of 43.74, P/B of 9.41, and EV/EBITDA of 17.39.
• No margin of safety: Price far above Graham Number of ₹483.51 and DCF value of ₹1615.91.
• Growth not enough to justify price: PEG ratio of 3.26 and dividend yield of only 0.75%.
• Market cap of ₹32,971 Cr leaves little room for error if earnings growth slows.

AI Analysis

J B Chemicals is the kind of company I might admire, but not the price I would pay. It earns an ROE of 21.95% and an ROCE of 25.79%, and it does this with a debt-to-equity ratio of zero. That combination is rare. Free cash flow of ₹606 Cr, a Piotroski score of 8/9, and an Altman Z-score of 7.29 all point to a financially sound operation. Promoter holding of 48.78% also aligns owners with minority shareholders. Growth is steady rather than spectacular: five-year revenue CAGR is 13.91%, sales grew 9.47%, and profits rose 17.77%. Latest quarter net profit of ₹198 Cr on sales of ₹1,065 Cr reflects the same disciplined operation. This is a stalwart business with a decent moat built on execution and balance sheet strength, not an exciting new venture. But valuation is where my enthusiasm stops. At ₹2011.50, the stock trades at 43.74 times earnings and 9.41 times book value. The Graham Number is only ₹483.51, giving a margin of safety of negative 324.71%. Even a conservative DCF estimate of ₹1615.91 is below the current price. The PEG ratio of 3.26 tells me the market is paying more than three times the profit growth for this quality. Dividend yield of just 0.75% provides little comfort while waiting. As Graham said, price is what you pay, value is what you get. Here, the market is already demanding years of flawless performance. I would keep the business on my watchlist, but I would not buy at this price. Let earnings grow into the valuation, or let the price fall closer to intrinsic value. Until then, patience remains my best friend.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer